[1] HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018,553(7689):446-454. [2] WEI T, WEILER S, TÓTH M, et al. YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells[J]. Oncogene, 2019, 38(27):5541-5550. [3] ZHAO B, LI L, LEI Q Y, et al. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version[J]. Genes Dev, 2010,24(9):862-874. [4] HAO Y W, CHUN A, CHEUNG K, et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP[J]. J Biol Chem, 2008,283(9):5496-5509. [5] LAI C J, LIN C Y, LIAO W Y, et al. CD44 promotes migration and invasion of docetaxel-resistant prostate cancer cells likely via induction of hippo-Yap signaling[J]. Cells, 2019,8(4):E295. [6] MOROOSHI T, HAYASHI T, PAN W W, et al. The hippo pathway kinases LATS1/2 suppress cancer immunity[J]. Cell, 2016,167(6):1525-1539. [7] LO S F, STRANO S, BLANDINO G. YAP and TAZ in lung cancer: oncogenic role and clinical targeting[J]. Cancers (Basel), 2018,10(5):E137. [8] WANG E Y, CHENG J C, THAKUR A, et al. YAP transcriptionally regulates ErbB2 to promote liver cell proliferation[J]. Biochim Biophys Acta, 2018,1861(9):854-863. [9] ZHUANG M, ZHAO S L, JIANG Z, et al. MALAT1 sponges miR-106b-5p to promote the invasion and metastasis of colorectal cancer via SLAIN2 enhanced microtubules mobility[J]. EBioMedicine, 2019,41:286-298. [10] MOROISHI T, HAYASHI T, Pan W W, et al. The hippo pathway kinases lats1/2 suppress cancer immunity[J]. Cell, 2016,167(6):1525-1539,e17. [11] ZHAO Z, CHEN C, LIU Y, et al. 17β-Estradiol treatment inhibits breast cell proliferation, migration and invasion by decreasing MALAT-1 RNA level[J]. Biochem Biophys Res Commun, 2014,445(2):388-393. [12] WANG J Y, WANG H M, ZHANG Y, et al. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer[J]. Cell Signal, 2014,26(5):1048-1059. [13] CHAN S W, LIM C J, CHONG Y F, et al. Hippo pathway-independent restriction of TAZ and YAP by angiomotin[J]. J Biol Chem, 2011,286(9):7018-7026. [14] LIANG Z G, WANG Y Y, SHEN Z Y, et al. Fascin 1 promoted the growth and migration of non-small cell lung cancer cells by activating YAP/TEAD signaling[J]. Tumour Biol, 2016,37(8):10909-10915. [15] GUO J W, WU Y, YANG L J, et al. Repression of YAP by NCTD disrupts NSCLC progression[J]. Oncotarget, 2017,8(2):2307-2319. [16] TRIPATHI V, ELLIS J D, SHEN Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation[J]. Mol Cell, 2010,39(6):925-938. [17] MACIAS S, PLASS M, STAJUDA A, et al. DGCR8 HITS-CLIP reveals novel functions for the microprocessor[J]. Nat Struct Mol Biol, 2012,19(8): 760-766. [18] MIYAGAWA R, TANO K, MIZUNO R, et al. Identification of cis-and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles[J]. RNA, 2012,18(4):738-751. [19] JI P, DIEDERICHS S, WANG W B, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer[J]. Oncogene, 2003,22(39):8031-8041. [20] GUTSCHER T, HÄMMERLE M, EISSMANN M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells[J]. Cancer Res, 2013,73(3):1180-1189. [21] TANO K, MIZUNO R, OKADA T, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes[J]. FEBS Lett, 2010,584(22):4575-4580. [22] ZHAO J, LI X N, YANG Y, et al. Effect of YAP1 silencing on esophageal cancer[J]. Onco Targets Ther, 2016,9:3137-3146. [23] DONG L, LIN F, WU W J, et al. Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell[J]. J Cancer, 2016,7(14):2132-2138. [24] ZANCONATO F, CORDENONSI M, PICCOLO S. YAP/TAZ at the roots of cancer[J]. Cancer Cell, 2016,29(6):783-803. |